Anti-cancer flower power

August 25, 2008,

Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer? Prof. Eliezer Flescher of The Sackler Faculty of Medicine, Tel Aviv University thinks so. He and his colleagues have developed an anti-cancer drug based on a decade of research into the commercial applications of the compound Jasmonate, a synthetic compound derived from the flower itself. Prof. Flescher began to research the compound about a decade ago, and with his recent development of the drug, his studies have now begun to bear meaningful fruit.

"Acetylsalicylic acid (aspirin) is based on a plant stress hormone," says Prof. Flescher. "I asked myself, 'Could there be other plant stress hormones that have clinical efficacy?' While various studies have suggested that aspirin can prevent cancer, especially colon cancer, I realized that there could be a chance to find a potent plant hormone that could fight cancer even better. I pinpointed jasmonate."

Both blood cancers and solid tumors seem to be responsive to the jasmonate compound, known also as methyl jasmonate. Prof. Flescher refers to it as the "jasmonate scaffold," a basis for developing a series of chemical derivatives. In terms of bioavailability and safety, early first-in-man studies have proven successful, and Prof. Flescher is hopeful that an anti-cancer drug based on jasmonate could be on the shelf in America within four years through the activity of Sepal-Pharma which licensed his research from Ramot, the technology transfer arm of Tel Aviv University.

Normally drug development takes much longer. "The jasmonate compound is used widely in agriculture and in cosmetics," says Prof. Flescher. "Proven to be non-toxic, it has the same regulatory status as table salt. That and the fact we are working on a natural chemical gives us a good starting point for launching a new drug."

Other research groups are taking notice. Since Prof. Flescher started publishing papers on jasmonate (most recently in the academic journal Oncogene), six new research groups around the world have initiated research on the subject.

Peer commentary in Oncogene is positive about Prof. Flescher's promising research. "Methyl jasmonate," says the commentary, "has already been shown to have selective anticancer activity in preclinical studies, and this finding may stimulate the development of a novel class of small anticancer compounds."

Source: American Friends of Tel Aviv University

Related Stories

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.